Abstract:Background： Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) is a progressive autosomal dominant neurodegenerative disease caused by abnormal CAG repeats in exon 10 of ATXN3 . The accumulation of the mutant ataxin3 proteins carrying polyglutamine (polyQ) lead to selective degeneration of neurons. Therapeutic strategies were used to inhibit mutant ATXN3 expression, including antisense oligonucleotides, RNA interference and more recently CRISPR/Cas9 genome-editing based approaches. Since the pathogenesis of SCA3 has not been fully elucidated, and no effective therapies can be used, it is crucial to investigate the pathogenesis and seek new therapeutic strategies of SCA3/MJD. Methods: Here we used the paired sgRNA/Cas9 nickases and Cre-loxP mediated homologous recombination (HR) strategy to precisely modify the abnormal CAG expansions in the ATXN3 of SCA3/MJD patient derived induced pluripotent stem cells (SCA3/MJD-iPSCs). Meanwhile, we investigated the disease related phenotypes in differentiated neurons, including electrophysiological characteristics, IC2-positive aggregations, mitochondrial membrane potentials (MMPs), glutathione (GSH) expressions, intracellular reactive oxygen species (ROS), Ca 2+ concentrations and malondialdehyde (MDA) levels. Results: SCA3/MJD-iPSCs can be corrected by the replacement of the abnormal CAG expansions with normal repeats using HR. Besides, corrected SCA3/MJD-iPSCs retained pluripotent and normal karyotype, which could be differentiated into neuron cells (NCs) and maintained electrophysiological characteristics. The expression of differentiation markers and electrophysiological characteristics were similar among the control individuals, SCA3/MJD patients and isogenic control SCA3/MJD groups. Furthermore, this study proved that the phenotypic abnormalities in SCA3/MJD-iPSCs derived NCs, including aggregated polyQ toxic protein, decreased MMPs and GSH expressions, increased ROS, Ca 2+ concentrations and MDA levels, all were rescued in the corrected SCA3/MJD-NCs. Conclusion: The present study firstly suggested that the genetically corrected SCA3/MJD-iPSCs and associated phenotypic abnormalities, which will provide an ideal models for molecular mechanism research and autologous stem cell therapy.

Chemical chaperones reduce aggregate formation and cell death caused by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch

Toward understanding Machado–Joseph disease

Research on Screening and Identification of Proteins Interacting with Ataxin-3.

PolyQ-expanded Ataxin-3 Interacts with Full-Length Ataxin-3 in a Polyq Length-Dependent Manner

Phosphorylation of ataxin-3 by glycogen synthase kinase 3beta at serine 256 regulates the aggregation of ataxin-3

Phosphorylation of Ataxin-3 by Glycogen Synthase Kinase 3β at Serine 256 Regulates the Aggregation of Ataxin-3

Polyglutamine-expanded ataxin-3 is degraded by autophagy

The deubiquitinase function of ataxin-3 and its role in the pathogenesis of Machado-Joseph disease and other diseases

Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

Astragaloside IV reduces mutant Ataxin-3 levels and supports mitochondrial function in Spinocerebellar Ataxia Type 3

Gene Mutation and Clinical Analysis in Machado-Joseph Disease

Small Molecules Inducing Autophagic Degradation of Expanded Polyglutamine Protein through Interaction with Both Mutant ATXN3 and LC3

Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity

Sumo-1 Modification On K166 Of Polyq-Expanded Ataxin-3 Strengthens Its Stability And Increases Its Cytotoxicity

Fibril-forming motif of non-expanded ataxin-3 revealed by scanning proline mutagenesis

In vivo suppression of polyglutamine aggregation via co-condensation of the molecular chaperone DNAJB6

Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics

Spinocerebellar Ataxia Type 3 Pathophysiology—Implications for Translational Research and Clinical Studies

Characterization of a Brain-enriched Chaperone, MRJ, That Inhibits Huntingtin Aggregation and Toxicity Independently

Ataxin-3, the MJD1 Gene Product, Interacts with the Two Human Homologs of Yeast DNA Repair Protein RAD23, HHR23A and HHR23B

CRISPR/Cas9&nbsp;Mediated Gene Modification Ameliorates Abnormal Phenotypes in SCA3/MJD&nbsp;Disease Patient Derived Induced Pluripotent Stem Cells